We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11,988.00
Bid: 12,016.00
Ask: 12,020.00
Change: -38.00 (-0.32%)
Spread: 4.00 (0.033%)
Open: 12,070.00
High: 12,144.00
Low: 11,882.00
Prev. Close: 12,026.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Broker tips: Henderson Group, AstraZeneca, IAG

Mon, 14th Sep 2015 16:39

(ShareCast News) - Exane BNP Paribas took a look at UK asset managers, noting that their shares have sold off sharply, making for an enticing entry point."Equity market volatility is a risk to inflows, but historically the impact has been temporary and flows into other asset classes do not suffer as much. Unless the market falls sharply, we think the outlook is strong."Exane initiated coverage of Henderson Group at 'outperform' with a 310 price target, saying it's the bank's top pick among the UK asset managers. It said the company has the best flow prospects and margin dynamics and is the most exposed to growth areas in asset management.It started Man Group at 'outperform' with a 190p price target, saying there's a high probability the company will make further acquisitions in the next 12-24 months. "Our analysis of previous deals shows that they have been value-accretive," it said.Coverage of Aberdeen Asset Management was initiated at 'underperform' with a 270p price target. It said Abederdeen has concentrated exposures to three flagship desks from which it expects further material outflows - global, global emerging markets and Asia Pacific equities - which together make up 60% of group revenues.Deutsche Bank upgraded AstraZeneca to 'buy' from 'hold' and raised its price target to 5,700p from 4,850p.The bank said it's increasingly confident in AstraZeneca's ability to deliver a return to strong growth from a base in 2017.Deutsche said while execution risks remain, the shares offer positive risk-reward and a level of upside optionality not available elsewhere in EU large-cap pharma sector.It noted that AZN's shares have underperformed EU pharma by more than 10% in 2015 and are trading at a discount to peers on a 2016 price-to-earnings ratio.Things were looking up for up for IAG shares in 2016 given improved pricing on its Transatlantic routes, the pricing behaviour within the sector in general and the stock's then current valuation, analysts at Credit Suisse said on Monday.The company's pricing in the third quarter "inspires confidence", making underlying growth of 49% in earnings before interest and taxes in the second half of 2015 "likely", analyst Neil Glynn said in a research note sent to clients.Glynn estimated the company's revenues would expand by 38% in 2016 if Aer Lingus was included and by 31% if not.Underpinning his argument, he pointed out how IAG's valuation relative to that of the top ten global airlines illustrated a 20% re-rating potential, suggesting the stock should trade at a lease-adjusted EV/IC ratio of 1.8 or six times EV/EBITDAR.On the back of the above the Swiss broker upped its target price on IAG stock by 14% to 852p from 750p while reiterating its 'outperform' recommendation.
More News
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more
4 Apr 2024 13:09

UK shareholder meetings calendar - next 7 days

Friday 5 April 
Faron Pharmaceuticals LtdAGM
VPC Specialty Lending Investments PLCGM re capital return via B share scheme
Monday 8 April 
Premier African Minerals LtdAGM
Tuesday 9 April 
Ethernity Networks LtdEGM re board appointments and option grants
Wednesday 10 April 
Valereum PLCAGM
Wincanton PLCGM re takeover by GXO Logistics Inc
Thursday 11 April 
AstraZeneca PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 17:22

UK's FTSE 100 pressured by stronger pound; miners climb

FTSE 100 flat, FTSE 250 up 0.2%

*

Read more
3 Apr 2024 11:02

CORRECT: AstraZeneca, Daiichi make US progress with licence approvals

(Correcting the description of extravascular haemolysis' effects on patients with paroxysmal nocturnal haemoglobinuria)

Read more
2 Apr 2024 15:22

London close: Stocks turn red on return from Easter break

(Sharecast News) - UK stocks experienced a downturn by the end of trading on Tuesday, as investors resumed activity following the extended weekend, with initial gains reversed by the close ahead of a week marked by a number of key economic data releases.

Read more
2 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth

(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data across the globe.

Read more
2 Apr 2024 10:25

AstraZeneca and Daiichi make US progress with latest licence approvals

(Alliance News) - AstraZeneca PLC on Tuesday noted significant progress for two of its clinical-stage treatments in the US.

Read more
2 Apr 2024 09:54

LONDON BROKER RATINGS: Bernstein starts AstraZeneca at 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
2 Apr 2024 09:09

LONDON MARKET OPEN: FTSE 100 up as oil majors and gold miners shine

(Alliance News) - Stock prices in London opened higher on Tuesday, in confident trade following the long Easter weekend, ahead of a UK manufacturing sector reading later in the morning.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.